Actelion

Actelion, a pharma company with a focus on pulmonary arterial hypertension (PAH) and other rare diseases, was founded in 1997. Their notable drug, Tracleer (bosentan), was among the first PAH-specific therapies. Additionally, they have developed Opsumit and Uptravi for the treatment of PAH. With a strong emphasis on research and development, Actelion's commitment to addressing unmet medical needs has been recognized in the scientific community.